Sagimet registers Phase 3 trial of denifanstat in moderate to severe acne vulgaris
The study, first posted on ClinicalTrials.gov on October 7, 2026, plans to enroll 800 participants and begin in October 2026. After a 12-week treatment phase, about 530 participants may consent to a 40-week open-label extension.
Primary source
ClinicalTrials.gov registry record, October 7, 2026
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne
Read the source: Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation